List of Figures

Figures	*Title*	*page*
2.1	General representation of ubiquitin proteasome pathway and its enzymes	*8*
2.2	An illustration of orchestration of factors involved in neurodevelopment and neurodegeneration	*10*
2.3	Overview of current understanding of amyloids	*15*
2.4	An overview of orchestration of cellular proteolytic machinery to reestablish homeostasis	*19*
3.1	*Lanosterol treatment upregulates cellular autophagy and induces co-chaperone CHIP expression*	*22*
3.2	*Treatment of lanosterol enhances the mRNA expression level of CHIP*	*23*
3.3	*Time-dependent treatment of lanosterol increases cellular level of CHIP protein*	*24*
3.4	*Lanosterol modulates CHIP levels in concentration-dependent manner*	*24*
3.5	*Expression of GFP-wtCAT plasmid constructs*	*25*
3.6	*Effect of chloroquine treatment on the expression of GFP-wtCAT*	*25*
3.7	*Lanosterol enhances the clearance of a mutant bona-fide misfolded proteins*	*26*
3.8	*Chloroquine treatment enhances the aggregation propensity of modeled misfolded protein*	*26*
3.9	*Lanosterol reduces the intracellular perinuclear accumulation of heat-denatured luciferase protein*	*27*
3.10	*Effect of lanosterol on the degradation of heat-denatured luciferase protein*	*28*
3.11	*Effects of lanosterol treatment on overall cellular health*	*29*
3.12	*Expression of SOD1-WT plasmid constructs*	*30*
3.13	*Effects of autophagy inhibition on the aggregation of ubiquitinated cellular proteins*	*30*
3.14	*Lanosterol suppresses the mutant SOD1 aggresomes formation in cells*	*31*
3.15	*Higher accumulation of mutant SOD1-G37R protein following autophagy inhibition*	*31*
3.16	*Wild-type alpha-synuclein expression analysis*	*32*
3.17	*Effects of administration of chloroquine on the expression of α-synuclein*	*32*
3.18	*Treatment of lanosterol reduces aggregation of mutant α–synuclein*	*33*
3.19	*Inhibition of autophagy overturns the anti-aggregatory effects of lanosterol*	*33*
3.20	*Representation of interaction of lanosterol with CHIP TPR domain*	*34*
3.21	*Lanosterol stabilizes co-chaperone CHIP*	*35*
3.22	*Expression of ataxin-3(Q28) plasmid constructs*	*35*
3.23	*Inhibition of autophagy leads to increased accumulation of normal ataxin-3(Q28) containing proteins*	*36*
3.24	*Lanosterol induces suppression of pathogenic ataxin-3 polyglutamine protein aggregation in cells*	*36*
3.25	*Administration of chloroquine ameliorates the cytoprotective effects of lanosterol*	*37*
3.26	*Visualization of normal huntingtin protein expression in Cos-7 cells*	*38*
3.27	*Effects of inhibition of cellular autophagic flux on the expression of normal huntingtin protein*	*38*
3.28	*Treatment of lanosterol results in decrease of cytoplasmic misfolded inclusions of expanded huntingtin polyglutamine aggregates*	*39*
3.29	*Monitoring of impact of chloroquine treatment on the formation of perinuclear inclusions of polyglutamine-containing huntingtin inside the cells*	*39*
3.30	*Lanosterol reduces misfolded protein aggregation*	*40*
3.31	*Lanosterol alleviates stress-induced cytotoxicity*	*41*
3.32	*Suppression of overall cytoplasmic aggregate formation following lanosterol treatment*	*42*
4.1	*Ibuprofen treatment causes accumulation of ubiquitinated proteins*	*48*
4.2	*Visualization of morphological changes caused by ibuprofen treatment*	*48*
4.3	*Treatment of ibuprofen disturbs proteasome function and induces cytotoxicity*	*49*
4.4	*Exposure of ibuprofen induces loss of chymotrypsin-like proteasome activity in dose-dependent manner*	*50*
4.5	*Time-dependent loss of chymotrypsin-like proteasomal activity in response to ibuprofen administration*	*50*
4.6	*Ibuprofen also suppresses post-glutamyl peptide hydrolase-like activity of proteasome*	*51*

4.7	*Time-dependent inhibition of post-glutamyl peptide hydrolase activity of 20S proteasome*	51
4.8	*Ibuprofen treatment leads to stabilization of misfolded proteins in cells*	52
4.9	*Effect of ibuprofen treatment on soluble fraction of pathogenic huntingtin protein*	53
4.10	*Ibuprofen treatment stabilizes ubiquitinated proteins inside the cells*	54
4.11	*Concentration-dependent cytotoxicity conferred by ibuprofen*	54
4.12	*Ibuprofen presents in silico interaction with proteasomal subunits*	55
4.13	*Enhanced accumulation of cytoplasmic ubiquitinated proteins following ibuprofen-mediated proteasomal inhibition*	56
4.14	*Bright-field image micrographs of ibuprofen treated cells*	56
4.15	*Formation of aggresomes of misfolded proteins response to ibuprofen treatment in cells*	57
4.16	*Ibuprofen mediates stabilization of IκB-α*	58
4.17	*Downregulation of NF-κB transcriptional activity in response to ibuprofen treatment*	58
4.18	*Ibuprofen causes stabilization of aggregation-prone misfolded protein species*	59
4.19	*Treatment of ibuprofen accelerates the accumulation of proteasome and ubiquitin-positive protein aggregates*	59
4.20	*Proteasomal inhibition by ibuprofen leads to increased accumulation of cell cycle regulatory proteins p53 and cyclin-dependent kinase inhibitor p27*	60
4.21	*Ibuprofen induces cytoplasmic accumulation of pro-apoptotic proteasomal target proteins*	60
4.22	*Ibuprofen treatment induces apoptosis and causes nuclear morphological changes*	61
4.23	*Time-dependent assessment of apoptosis by flow cytometry using annexin V-FITC and propidium iodide double staining*	62
4.24	*Representation of DNA fragmentation following treatment of inbuprofen*	63
4.25	*Ibuprofen treatment induces cytochrome c release during apoptosis*	64
4.26	*Higher accumulation of cytochrome c following the treatment of cells with ibuprofen*	64
4.27	*Ibuprofen treatment leads to mitochondrial depolarization*	65
4.28	Analysis of ibuprofen-mediated mitochondrial alterations using JC-1 staining and fluorescence analysis	65